Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study.
Identifieur interne : 001F11 ( Ncbi/Merge ); précédent : 001F10; suivant : 001F12Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study.
Auteurs : Ji Youn Kim [Corée du Sud] ; Eun Joo Chung ; Won Yong Lee ; Hee Young Shin ; Gyeong Han Lee ; Yearn-Seong Choe ; Yong Choi ; Byeong Joon KimSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Adult, Aged, Electric Stimulation (methods), Female, Humans, Male, Middle Aged, Parkinson Disease (radionuclide imaging), Parkinson Disease (therapy), Positron-Emission Tomography, Raclopride (metabolism), Severity of Illness Index, Transcranial Magnetic Stimulation (methods), Tritium (diagnostic use).
- MESH :
- chemical , diagnostic use : Tritium.
- chemical , metabolism : Raclopride.
- methods : Electric Stimulation, Transcranial Magnetic Stimulation.
- radionuclide imaging : Parkinson Disease.
- therapy : Parkinson Disease.
- Adult, Aged, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Severity of Illness Index.
Abstract
Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [(11)C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off-medication, two series of 15 trains of 5 Hz-frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (-4.9% and -6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (-6.6%, P > 0.05 and -12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 +/- 14.1 to 32.0 +/- 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS.
DOI: 10.1002/mds.21787
PubMed: 17999422
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002448
- to stream PubMed, to step Curation: 002448
- to stream PubMed, to step Checkpoint: 002023
Links to Exploration step
pubmed:17999422Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study.</title><author><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji Youn" last="Kim">Ji Youn Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name></author><author><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name></author><author><name sortKey="Shin, Hee Young" sort="Shin, Hee Young" uniqKey="Shin H" first="Hee Young" last="Shin">Hee Young Shin</name></author><author><name sortKey="Lee, Gyeong Han" sort="Lee, Gyeong Han" uniqKey="Lee G" first="Gyeong Han" last="Lee">Gyeong Han Lee</name></author><author><name sortKey="Choe, Yearn Seong" sort="Choe, Yearn Seong" uniqKey="Choe Y" first="Yearn-Seong" last="Choe">Yearn-Seong Choe</name></author><author><name sortKey="Choi, Yong" sort="Choi, Yong" uniqKey="Choi Y" first="Yong" last="Choi">Yong Choi</name></author><author><name sortKey="Kim, Byeong Joon" sort="Kim, Byeong Joon" uniqKey="Kim B" first="Byeong Joon" last="Kim">Byeong Joon Kim</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.21787</idno><idno type="RBID">pubmed:17999422</idno><idno type="pmid">17999422</idno><idno type="wicri:Area/PubMed/Corpus">002448</idno><idno type="wicri:Area/PubMed/Curation">002448</idno><idno type="wicri:Area/PubMed/Checkpoint">002023</idno><idno type="wicri:Area/Ncbi/Merge">001F11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study.</title><author><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji Youn" last="Kim">Ji Youn Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name></author><author><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name></author><author><name sortKey="Shin, Hee Young" sort="Shin, Hee Young" uniqKey="Shin H" first="Hee Young" last="Shin">Hee Young Shin</name></author><author><name sortKey="Lee, Gyeong Han" sort="Lee, Gyeong Han" uniqKey="Lee G" first="Gyeong Han" last="Lee">Gyeong Han Lee</name></author><author><name sortKey="Choe, Yearn Seong" sort="Choe, Yearn Seong" uniqKey="Choe Y" first="Yearn-Seong" last="Choe">Yearn-Seong Choe</name></author><author><name sortKey="Choi, Yong" sort="Choi, Yong" uniqKey="Choi Y" first="Yong" last="Choi">Yong Choi</name></author><author><name sortKey="Kim, Byeong Joon" sort="Kim, Byeong Joon" uniqKey="Kim B" first="Byeong Joon" last="Kim">Byeong Joon Kim</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Electric Stimulation (methods)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson Disease (therapy)</term><term>Positron-Emission Tomography</term><term>Raclopride (metabolism)</term><term>Severity of Illness Index</term><term>Transcranial Magnetic Stimulation (methods)</term><term>Tritium (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Tritium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Raclopride</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation</term><term>Transcranial Magnetic Stimulation</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Positron-Emission Tomography</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [(11)C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off-medication, two series of 15 trains of 5 Hz-frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (-4.9% and -6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (-6.6%, P > 0.05 and -12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 +/- 14.1 to 32.0 +/- 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17999422</PMID><DateCreated><Year>2008</Year><Month>02</Month><Day>04</Day></DateCreated><DateCompleted><Year>2008</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study.</ArticleTitle><Pagination><MedlinePgn>207-11</MedlinePgn></Pagination><Abstract><AbstractText>Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [(11)C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off-medication, two series of 15 trains of 5 Hz-frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (-4.9% and -6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (-6.6%, P > 0.05 and -12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 +/- 14.1 to 32.0 +/- 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS.</AbstractText><CopyrightInformation>2007 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji Youn</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eun Joo</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Won Yong</ForeName><Initials>WY</Initials></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Hee Young</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Gyeong Han</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Yearn-Seong</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byeong Joon</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>430K3SOZ7G</RegistryNumber><NameOfSubstance UI="D020891">Raclopride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004558">Electric Stimulation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D049268">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020891">Raclopride</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050781">Transcranial Magnetic Stimulation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014316">Tritium</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21787</ArticleId><ArticleId IdType="pubmed">17999422</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country><settlement><li>Séoul</li></settlement></list><tree><noCountry><name sortKey="Choe, Yearn Seong" sort="Choe, Yearn Seong" uniqKey="Choe Y" first="Yearn-Seong" last="Choe">Yearn-Seong Choe</name><name sortKey="Choi, Yong" sort="Choi, Yong" uniqKey="Choi Y" first="Yong" last="Choi">Yong Choi</name><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name><name sortKey="Kim, Byeong Joon" sort="Kim, Byeong Joon" uniqKey="Kim B" first="Byeong Joon" last="Kim">Byeong Joon Kim</name><name sortKey="Lee, Gyeong Han" sort="Lee, Gyeong Han" uniqKey="Lee G" first="Gyeong Han" last="Lee">Gyeong Han Lee</name><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name><name sortKey="Shin, Hee Young" sort="Shin, Hee Young" uniqKey="Shin H" first="Hee Young" last="Shin">Hee Young Shin</name></noCountry><country name="Corée du Sud"><noRegion><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji Youn" last="Kim">Ji Youn Kim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001F11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:17999422
|texte= Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17999422" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |